$Acrivon Therapeutics (ACRV.US)$ NEWS Acrivon Therapeutics P...
NEWS
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368
Acrivon Therapeutics, Inc. announced data from two posters presented at the AACR Annual Meeting. ACR-2316, a dual WEE1/PKMYT1 inhibitor, showed potent anticancer activity in preclinical studies. AP3 profiling identified ULDG as a sensitizer for resistant ovarian cancer cells to ACR-368, a CHK1/2 inhibitor. Acrivon's precision proteomics-based approach in drug discovery and development was highlighted.
Acrivon Therapeutics, Inc. announced data from two posters presented at the AACR Annual Meeting. ACR-2316, a dual WEE1/PKMYT1 inhibitor, showed potent anticancer activity in preclinical studies. AP3 profiling identified ULDG as a sensitizer for resistant ovarian cancer cells to ACR-368, a CHK1/2 inhibitor. Acrivon's precision proteomics-based approach in drug discovery and development was highlighted.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1089Followers
68Following
7500Visitors
Follow